# Melphalan, Lenalidomide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis

> **NCT00679367** · PHASE2 · COMPLETED · sponsor: **Boston Medical Center** · enrollment: 16 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** dexamethasone
- **DRUG:** lenalidomide
- **DRUG:** melphalan

## Key facts

- **NCT ID:** NCT00679367
- **Lead sponsor:** Boston Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-05
- **Primary completion:** 2015-05
- **Final completion:** 2015-05
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2017-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00679367

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00679367, "Melphalan, Lenalidomide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT00679367. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*